drugset / Trial / NCT05646784

Gut Microbiota in Mood Disorders in Lebanese Population

NCT05646784 ↗

RandomizedParallel-groupQuadruple-blindHealth-services research

Summary

This study aims to evaluate the pathophysiological aspects of the role of inflammation and gut microbiota in mood disorders, in particular in depression, and their therapeutic implications on a cohort of the Lebanese population. Specific objective: The evaluation of probiotic intake (CEREBIOME®, Lallemand Health Solutions Inc., Mirabel, Canada) on the inflammatory state, gut bacterial profile and the depressive state. Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment.

Timeline

Start
2024-01-24
Primary completion
2025-01-31
Completion
2025-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cerebiome Other / unclassified — Oral

Indications